Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study

MWC. Verbeek, BS. Rodríguez, L. Sedek, A. Laqua, C. Buracchi, M. Buysse, M. Reiterová, E. Oliveira, D. Morf, SR. Oude Alink, S. Barrena, S. Kohlscheen, S. Nierkens, M. Hofmans, P. Fernandez, ES. de Costa, E. Mejstrikova, T. Szczepanski, L. Slota,...

. 2024 ; 106 (4) : 252-263. [pub] 20230922

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019956

Grantová podpora
Fondo Europeo de Desarrollo Regional (FEDER)
LSHB-CT-2006-018708 European Commission
CB16/12/00400 CIBERONC
PI19/01183 Instituto de Salud Carlos III (ISCIII)
NU20J-07-00028 Ministry of Health of the Czech Republic
LX22NPO5102 National Institute for Cancer Research
European Union - Next Generation EU
DJCLS R 15/11 Deutsche José Carreras Leukämie-Stiftung
DJCLS 06R/2019 Deutsche José Carreras Leukämie-Stiftung
PCN-1-075/K/1/K Medical Univeristy of Silesia
Fondazione M. Tettamanti M. De Marchi ONLUS

Presence of minimal residual disease (MRD), detected by flow cytometry, is an important prognostic biomarker in the management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, data-analysis remains mainly expert-dependent. In this study, we designed and validated an Automated Gating & Identification (AGI) tool for MRD analysis in BCP-ALL patients using the two tubes of the EuroFlow 8-color MRD panel. The accuracy, repeatability, and reproducibility of the AGI tool was validated in a multicenter study using bone marrow follow-up samples from 174 BCP-ALL patients, stained with the EuroFlow BCP-ALL MRD panel. In these patients, MRD was assessed both by manual analysis and by AGI tool supported analysis. Comparison of MRD levels obtained between both approaches showed a concordance rate of 83%, with comparable concordances between MRD tubes (tube 1, 2 or both), treatment received (chemotherapy versus targeted therapy) and flow cytometers (FACSCanto versus FACSLyric). After review of discordant cases by additional experts, the concordance increased to 97%. Furthermore, the AGI tool showed excellent intra-expert concordance (100%) and good inter-expert concordance (90%). In addition to MRD levels, also percentages of normal cell populations showed excellent concordance between manual and AGI tool analysis. We conclude that the AGI tool may facilitate MRD analysis using the EuroFlow BCP-ALL MRD protocol and will contribute to a more standardized and objective MRD assessment. However, appropriate training is required for the correct analysis of MRD data.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019956
003      
CZ-PrNML
005      
20241024110828.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cyto.b.22143 $2 doi
035    __
$a (PubMed)37740440
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Verbeek, Martijn W C $u Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
245    10
$a Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study / $c MWC. Verbeek, BS. Rodríguez, L. Sedek, A. Laqua, C. Buracchi, M. Buysse, M. Reiterová, E. Oliveira, D. Morf, SR. Oude Alink, S. Barrena, S. Kohlscheen, S. Nierkens, M. Hofmans, P. Fernandez, ES. de Costa, E. Mejstrikova, T. Szczepanski, L. Slota, M. Brüggemann, G. Gaipa, G. Grigore, JJM. van Dongen, A. Orfao, VHJ. van der Velden
520    9_
$a Presence of minimal residual disease (MRD), detected by flow cytometry, is an important prognostic biomarker in the management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, data-analysis remains mainly expert-dependent. In this study, we designed and validated an Automated Gating & Identification (AGI) tool for MRD analysis in BCP-ALL patients using the two tubes of the EuroFlow 8-color MRD panel. The accuracy, repeatability, and reproducibility of the AGI tool was validated in a multicenter study using bone marrow follow-up samples from 174 BCP-ALL patients, stained with the EuroFlow BCP-ALL MRD panel. In these patients, MRD was assessed both by manual analysis and by AGI tool supported analysis. Comparison of MRD levels obtained between both approaches showed a concordance rate of 83%, with comparable concordances between MRD tubes (tube 1, 2 or both), treatment received (chemotherapy versus targeted therapy) and flow cytometers (FACSCanto versus FACSLyric). After review of discordant cases by additional experts, the concordance increased to 97%. Furthermore, the AGI tool showed excellent intra-expert concordance (100%) and good inter-expert concordance (90%). In addition to MRD levels, also percentages of normal cell populations showed excellent concordance between manual and AGI tool analysis. We conclude that the AGI tool may facilitate MRD analysis using the EuroFlow BCP-ALL MRD protocol and will contribute to a more standardized and objective MRD assessment. However, appropriate training is required for the correct analysis of MRD data.
650    _2
$a lidé $7 D006801
650    12
$a reziduální nádor $x patologie $x diagnóza $7 D018365
650    12
$a průtoková cytometrie $x metody $7 D005434
650    12
$a pre-B-buněčná leukemie $x patologie $x diagnóza $7 D015452
650    _2
$a dítě $7 D002648
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mladiství $7 D000293
650    _2
$a předškolní dítě $7 D002675
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mladý dospělý $7 D055815
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a imunofenotypizace $x metody $7 D016130
650    _2
$a senioři $7 D000368
650    _2
$a kojenec $7 D007223
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Rodríguez, Beatriz Soriano $u Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain $u Department of Medicine, University of Salamanca (USAL), Salamanca, Spain $u Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
700    1_
$a Sedek, Lukasz $u Department of Microbiology and Immunology, Medical University of Silesia in Katowice, Zabrze, Poland $u Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland
700    1_
$a Laqua, Anna $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany
700    1_
$a Buracchi, Chiara $u Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
700    1_
$a Buysse, Malicorne $u Department of Diagnostic Sciences, Ghent University, Ghent, Belgium $u Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium
700    1_
$a Reiterová, Michaela $u CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Oliveira, Elen $u Pediatrics Institute IPPMG, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
700    1_
$a Morf, Daniela $u Institute for Laboratory Medicine, Aarau, Switzerland
700    1_
$a Oude Alink, Sjoerd R $u Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
700    1_
$a Barrena, Susana $u Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain $u Department of Medicine, University of Salamanca (USAL), Salamanca, Spain $u Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
700    1_
$a Kohlscheen, Saskia $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany
700    1_
$a Nierkens, Stefan $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
700    1_
$a Hofmans, Mattias $u Department of Diagnostic Sciences, Ghent University, Ghent, Belgium $u Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium
700    1_
$a Fernandez, Paula $u Institute for Laboratory Medicine, Aarau, Switzerland
700    1_
$a de Costa, Elaine Sobral $u Pediatrics Institute IPPMG, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil $1 https://orcid.org/0000000253405816
700    1_
$a Mejstrikova, Ester $u CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Szczepanski, Tomasz $u Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland
700    1_
$a Slota, Lukasz $u Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia in Katowice, Katowice, Poland
700    1_
$a Brüggemann, Monika $u Department of Hematology, University of Schleswig-Holstein, Kiel, Germany
700    1_
$a Gaipa, Giuseppe $u Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
700    1_
$a Grigore, Georgiana $u Cytognos SL, Salamanca, Spain
700    1_
$a van Dongen, Jacques J M $u Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain $u Department of Medicine, University of Salamanca (USAL), Salamanca, Spain $u Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain $u Department of Immunology, Leiden University Medical Center (LUMC), The Netherlands
700    1_
$a Orfao, Alberto $u Translational and Clinical Research program, Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS, Salamanca, Spain $u Department of Medicine, University of Salamanca (USAL), Salamanca, Spain $u Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
700    1_
$a van der Velden, Vincent H J $u Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands $1 https://orcid.org/0000000194573763
773    0_
$w MED00013936 $t Cytometry. Part B, Clinical cytometry $x 1552-4957 $g Roč. 106, č. 4 (2024), s. 252-263
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37740440 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110822 $b ABA008
999    __
$a ok $b bmc $g 2202281 $s 1231929
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 106 $c 4 $d 252-263 $e 20230922 $i 1552-4957 $m Cytometry. Part B, Clinical cytometry $n Cytometry B Clin Cytom $x MED00013936
GRA    __
$p Fondo Europeo de Desarrollo Regional (FEDER)
GRA    __
$a LSHB-CT-2006-018708 $p European Commission
GRA    __
$a CB16/12/00400 $p CIBERONC
GRA    __
$a PI19/01183 $p Instituto de Salud Carlos III (ISCIII)
GRA    __
$a NU20J-07-00028 $p Ministry of Health of the Czech Republic
GRA    __
$a LX22NPO5102 $p National Institute for Cancer Research
GRA    __
$p European Union - Next Generation EU
GRA    __
$a DJCLS R 15/11 $p Deutsche José Carreras Leukämie-Stiftung
GRA    __
$a DJCLS 06R/2019 $p Deutsche José Carreras Leukämie-Stiftung
GRA    __
$a PCN-1-075/K/1/K $p Medical Univeristy of Silesia
GRA    __
$p Fondazione M. Tettamanti M. De Marchi ONLUS
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace